Zhou Xi, Fan Yang-Hua, Wang Yan, Wang Fu, Liu Yong
Department of orthopedics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College.
Department of Central laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing.
Medicine (Baltimore). 2019 Apr;98(17):e15251. doi: 10.1097/MD.0000000000015251.
Aberrant expression of long non-coding RNA Zinc finger E-box binding homeobox 1 antisense 1 (lncRNA ZEB1-AS1) can be detected in numerous malignancies. Therefore, a meta-analysis had been carried out in this study, aiming to examine the prognostic value of lncRNA ZEB1-AS1 in malignancies.
Electronic databases, such as PubMed, OVID as well as Web of Science, had been systemically retrieved from inception to February 14th, 2019. Besides, the hazard ratios (HRs), together with the corresponding 95% confidence intervals (CIs), had also been analyzed for determining the association of lncRNA ZEB1-AS1 expression with the overall survival (OS) and recurrence-free survival (RFS). In addition, the pooled odds ratios (ORs) would also be computed using the Stata SE12.0 software for evaluating the relationship of lncRNA ZEB1-AS1 expression with pathological factors.
A total of 21 original studies involving 1801 cancer patients had been enrolled into the current meta-analysis. As suggested by the pooled HR, high expression of lncRNA ZEB1-AS1 had displayed marked correlation with OS (HR = 2.16, 95% CI: 1.89-2.47) among cancer patients, and no significant heterogeneity was detected. Additionally, high expression of lncRNA ZEB1-AS1 was also markedly associated with RFS among cancer patients (pooled HR = 2.55, 95% CI: 1.61-4.03). Besides, the expression of lncRNA ZEB1-AS1 had displayed marked correlation with poor histological grade (PHG) (OR = 2.86, 95% CI: 2.11-3.87), high tumor stage (HTS) (OR = 3.81, 95% CI: 2.72-5.34) as well as lymph node metastasis (LNM) (OR = 3.33, 95% CI: 2.47-4.49). Additionally, no distinct asymmetry had been detected for RFS, PHG as well as HTS based on Begg funnel plot.
Taken together, high expression of lncRNA ZEB1-AS1 can predict the dismal OS, RFS, LNM, PHG, and HTS, indicating that lncRNA ZEB1-AS1 can be potentially used as a new biomarker to predict the dismal prognosis for cancer patients.
在众多恶性肿瘤中均可检测到长链非编码RNA锌指E盒结合同源框1反义1（lncRNA ZEB1-AS1）的异常表达。因此，本研究进行了一项荟萃分析，旨在探讨lncRNA ZEB1-AS1在恶性肿瘤中的预后价值。
从创刊至2019年2月14日，系统检索了PubMed、OVID以及Web of Science等电子数据库。此外，还分析了风险比（HR）及其相应的95%置信区间（CI），以确定lncRNA ZEB1-AS1表达与总生存期（OS）和无复发生存期（RFS）之间的关联。此外，还将使用Stata SE12.0软件计算合并比值比（OR），以评估lncRNA ZEB1-AS1表达与病理因素之间的关系。
本荟萃分析共纳入了21项涉及1801例癌症患者的原始研究。汇总HR显示，lncRNA ZEB1-AS1高表达与癌症患者的OS显著相关（HR = 2.16，95%CI：1.89 - 2.47），且未检测到显著异质性。此外，lncRNA ZEB1-AS1高表达也与癌症患者的RFS显著相关（汇总HR = 2.55，95%CI：1.61 - 4.03）。此外，lncRNA ZEB1-AS1的表达与低组织学分级（PHG）（OR = 2.86，95%CI：2.11 - 3.87）、高肿瘤分期（HTS）（OR = 3.81，95%CI：2.72 - 5.34）以及淋巴结转移（LNM）（OR = 3.33，95%CI：2.47 - 4.49）显著相关。此外，基于Begg漏斗图，在RFS、PHG以及HTS方面未检测到明显的不对称性。
综上所述，lncRNA ZEB1-AS1高表达可预测不良的OS、RFS、LNM、PHG和HTS，表明lncRNA ZEB1-AS1有可能作为一种新的生物标志物来预测癌症患者的不良预后。
